Výsledky vyhledávání - "M. D. Pegram"

Trastuzumab and chemotherapeutics: drug interactions and synergies

Autor: M D, Pegram, A, Lopez, G, Konecny, D J, Slamon

Publikováno v: Seminars in oncology. 27(6 Suppl 11)

Previous studies have shown a synergistic interaction between trastuzumab (Herceptin; Genentech, Inc, South San Francisco, CA) and the cytotoxic drug cisplatin in human breast cancer cells. To define the nature of the interaction between trastuzumab

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::bede50cd765da42d1a985774944cb699
https://pubmed.ncbi.nlm.nih.gov/11236023

Zobrazit plný text záznamu

Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptor-enhanced chemosensitivity

Autor: M D, Pegram, D J, Slamon

Publikováno v: Seminars in oncology. 26(4 Suppl 12)

The anti-HER-2/neu antibody trastuzumab (Herceptin; Genentech, San Francisco, CA) interferes with DNA repair induced by cisplatin and, as a result, promotes cytotoxicity in HER-2/neu-overexpressing tumor target cells in a synergistic fashion. This ef

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::c84cd6242a7094ee213d369c4548a0af
https://pubmed.ncbi.nlm.nih.gov/10482199

Zobrazit plný text záznamu

HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells

Autor: R J, Pietras, J, Arboleda, D M, Reese, N, Wongvipat, M D, Pegram, L, Ramos, C M, Gorman, M G, Parker, M X, Sliwkowski, D J, Slamon

Publikováno v: Oncogene. 10(12)

Growth of human breast cells is closely regulated by steroid hormone as well as peptide hormone receptors. Members of both receptor classes are important prognostic factors in human breast cancer. Clinical data indicate that overexpression of the HER

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::57d99e4bd8b416541dda738ffbd839be
https://pubmed.ncbi.nlm.nih.gov/7784095

Zobrazit plný text záznamu

Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells

Autor: R J, Pietras, B M, Fendly, V R, Chazin, M D, Pegram, S B, Howell, D J, Slamon

Publikováno v: Oncogene. 9(7)

Approximately 30% of human breast and ovarian cancers have amplification and/or overexpression of HER-2/neu gene which encodes a cell surface growth-factor receptor. Overexpression of this receptor, p185HER-2/neu, is associated with poor outcome and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::10a7a3303587df935f55d287366b1c8e
https://pubmed.ncbi.nlm.nih.gov/7911565

Zobrazit plný text záznamu

Utilization and clinical practice impact of an interactive tool for guiding choice of systemic adjuvant treatment (adj TX) for patients with early breast cancer (EBC)

Autor: Sandra M. Swain, J. A. Mortimer, Nicholas J. Robert, AD Bowser, Silvana Martino, D. Janssen, Robert W. Carlson, M. D. Pegram, Peter M. Ravdin

Publikováno v: Journal of Clinical Oncology. 29:6063-6063

6063 Background: Guidelines list more than 20 regimens as options for adjuvant breast cancer treatment. Adjuvant!Online provides risk assessment based on patient characteristics and expected risk r...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f490c5dc391410cff1c40c3521f5fbe8
https://doi.org/10.1200/jco.2011.29.15_suppl.6063

Zobrazit plný text záznamu

Phase I trial of weekly and every 3 weeks ixabepilone (Ix) and sunitinib (S) in advanced solid tumors (STs)

Autor: M. Kittaneh, A. J. Montero, K. Kovacs, V. D. Guardiola Amado, A. M. Flores, A. Ferrell, M. Vulfovich, M. D. Pegram, P. W. Benedetto, C. M. S. Rocha Lima, J. R. Merchan

Publikováno v: Journal of Clinical Oncology. 29:3081-3081

3081 Background: Ix is a cytotoxic microtubule-stabilizing agent with anti-proliferative and anti-angiogenic properties. S is a multi-targeted receptor tyrosine kinase inhibitor. IX and S combinati...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5df94e46d1d25e267fe23dbe5ca0ef29
https://doi.org/10.1200/jco.2011.29.15_suppl.3081

Zobrazit plný text záznamu

Neoadjuvant platinum-based chemotherapy (CT) for triple-negative locally advanced breast cancer (LABC): Retrospective analysis of 125 patients

Autor: A. Venkatraman, V. Guardiola, J. Hurley, Orlando Silva, C. Welsh, M. D. Pegram, C. R. Gomez, R. Larrieux, D. Franchesci, J. P. Leone

Publikováno v: Journal of Clinical Oncology. 27:625-625

625 Background: Triple-negative breast cancer (TNBC), defined by lack of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2, accounts for 15–20% of all breast cancers and is associated with poor prognosis. There

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d5518afddf8337c850e2f6f6954fd0a3
https://doi.org/10.1200/jco.2009.27.15_suppl.625

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání